Press coverage about HTG Molecular Diagnostics (NASDAQ:HTGM) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 47.0464485190552 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- HTG Molecular Diagnostics, Inc. (HTGM) CEO T. J. Johnson on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Critical Review: Horiba (HRIBF) vs. HTG Molecular Diagnostics (HTGM) (americanbankingnews.com)
- HTG Molecular Diagnostics Inc (HTGM) Expected to Post Quarterly Sales of $5.19 Million (americanbankingnews.com)
- Comparing Aethlon Medical (AEMD) & HTG Molecular Diagnostics (HTGM) (americanbankingnews.com)
- HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited (finance.yahoo.com)
A number of brokerages have recently issued reports on HTGM. HC Wainwright set a $7.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Tuesday, April 17th. ValuEngine raised HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Thursday, May 24th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $6.17.
Shares of HTG Molecular Diagnostics traded down $0.03, reaching $3.58, during trading hours on Friday, MarketBeat reports. 429,203 shares of the company’s stock were exchanged, compared to its average volume of 401,623. The company has a market cap of $102.57 million, a PE ratio of -2.00 and a beta of 1.46. The company has a current ratio of 9.80, a quick ratio of 9.59 and a debt-to-equity ratio of 0.31. HTG Molecular Diagnostics has a fifty-two week low of $1.59 and a fifty-two week high of $5.83.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Thursday, August 9th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. HTG Molecular Diagnostics had a negative return on equity of 215.21% and a negative net margin of 81.10%. The firm had revenue of $4.91 million for the quarter, compared to the consensus estimate of $5.30 million. equities analysts forecast that HTG Molecular Diagnostics will post -0.71 earnings per share for the current year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Further Reading: Trading Strategy Methods and Types
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.